Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CDA	978	CALCITRIOL	CHEMBL846		DrugBank
CDA	978	GEMCITABINE	CHEMBL888		NCI	12477049
CDA	978	PHENYLTHIOUREA	CHEMBL263376		PharmGKB
CDA	978	CYTARABINE	CHEMBL803		NCI	14744791, 12008078, 8791999
CDA	978	TETRAHYDROURIDINE	CHEMBL1236475		NCI	2932216
CDA	978	DEOXYCYTIDINE	CHEMBL66115		NCI	12008078

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CDA	rs2072671	CC	cytarabine	"toxicity","metabolism/PK"	not stated	as determined by measurement of cytidine deaminase (CDA) activity, which detoxifies the drug. Variants in the TPMT and CDA gene were examined, and this variant genotype along with the rs3215400 del/del genotype in the CDA gene were identified as possibly being associated with the cytarabine-induced toxicity, and may correlate with the deficiency in CDA activity observed through disregulation of CDA expression.	Genotype CC is associated with decreased clearance of cytarabine in children Lymphoma, T-Cell.	22379997	827922320
CDA	rs2072671	AA	gemcitabine	metabolism/PK	yes	Blood samples were collected from NSCLC patients for genotyping, and CDA enzyme activity assay. The authors measured CDA activity in vitro by incubating supernatant from lysed RBCs with gemcitabine. Formation of the gemcitabine metabolite dFdU was quantified and CDA enzyme activity was reported as pmol of dFdU/ hr/ mg of CDA protein. The authors combined the values for CC and AC and compared mean enzyme activity levels to AA activity levels.	Genotype AA is associated with decreased metabolism of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.	18600531	1184175032
CDA	rs12404655	AG + GG	ara-CTP	metabolism/PK	yes		Genotypes AG + GG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype AA.	30088438	1449752060
CDA	rs2072671	C	gemcitabine	"toxicity","metabolism/PK"	no	(*2 haplotype)	Allele C is not associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele A.	17194903	655386820
CDA	rs60369023	A	gemcitabine	"other","metabolism/PK"	yes	(decreased clearance)	Allele A is associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele G.	17194903	655386824
CDA	rs2072671	AA	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype AA is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.	18538445	981785480
CDA	rs1048977	CC	gemcitabine	"efficacy","toxicity"	no	Tumor response to therapy, progression free survival, and risk of neutropenia development did not significantly differ between genotype groups.	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	20665488	981793894
CDA	rs2072671	AA	cisplatin	efficacy	yes	This SNP was presented as CDA Lys27Gln. Patients homozygous for the wildtype allele (Lys/Lys) showed significantly longer time to progression (P=.006) and overall survival (P=.002) as compared to patients carrying the Gln allele.	Genotype AA is associated with increased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.	18347182	1183700701
CDA	rs1048977	C	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele C is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele T.	24361227	1184086196
CDA	rs2072671	A	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	24361227	1184086203
CDA	rs3215400	del/del	azacitidine	efficacy	no	A case study of a chronic myelomonocytic leukemia patient who displayed complete lack of response despite several cycles of azacitidine.	Genotype del/del is associated with increased resistance to azacitidine in people with Leukemia.	26556583	1447675015
CDA	rs2072671	C	gemcitabine	metabolism/PK	yes	However, this was not associated with toxicity.	Allele C is associated with decreased clearance of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.	21590444	1446900777
CDA	rs2072671	AA + AC	bevacizumab	efficacy	no	No significant association with response, progression-free survival (PFS) or overall survival (OS) was seen between the genotypes in multivariable analysis. However, in univariate analysis, there was a "nominally" significant association with OS - patients with the AA or AC genotype had longer OS as compared to those with the CC genotype (p=0.036). Formally significant was defined as p<0.0026, and nominally significant as p<0.05.	Genotypes AA + AC are not associated with response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype CC.	27995989	1448568292
CDA	rs60369023	G	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele G is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele A.	24361227	1184086208
CDA	rs818194	A	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele T.	24361227	1184086212
CDA	rs1048977	CC	gemcitabine	efficacy	yes	Response rate and median time to progression were significantly higher in patients with the CC genotype than in patients with the CT or TT genotype. Median survival time was not significantly different among patients with differing genotypes.	Genotype CC is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	18538445	981785504
CDA	rs1048977	TT	gemcitabine	metabolism/PK	yes	Gemcitabine, dFdCTP, and dFdU plasma concentrations were measured before (5, 15, 30, 45 min) and after gemcitabine infusion (1, 1.25, 1.5, 2, 6, 24, 48, 72 hrs). Population pharmacokinetic analysis of gemcitabine and metabolites (dFdU, dFdCTP) were performed by non-linear mixed effects modeling. Although this SNP was not significantly associated with gemcitabine clearance, it was significantly associated with clearance of the gemcitabine metabolite dFdU. Pharmacokinetics of dFdU were described by a three-compartment model. CDA rs1048977 genotype and creatine clearance were significant covariates in the final model to be predict rate of clearance of dFdU, the deaminated metabolite of gemcitabine.	Genotype TT is associated with decreased metabolism of gemcitabine as compared to genotypes CC + CT.	24300978	1184174878
CDA	rs2072671	C	capecitabine	metabolism/PK	no	No significant differences in the area under the concentration-time curve from 0 to infinity (AUCinf) were seen between any of the genotypes (CC, AC, AA). Nor were any significant differences seen between these genotypes when considering the capecitabine metabolites 5'-DFCR, 5'-DFUR or 5'FU (5'-fluorouracil). Please note alleles have been complemented to the plus chromosomal strand.	Allele C is not associated with metabolism of capecitabine in people with Breast Neoplasms as compared to allele A.	23588952	1183682259
CDA	rs2072671	AA	gemcitabine	efficacy	yes	Patients with the AA genotype had a better response to gemcitabine therapy than patients with either the AC or the CC genotype. However, progression free survival did not significantly differ between genotype groups. There were four SNPs in this study that, when taken together, affected progression free survival: rs183484, rs2072671, rs760370, and rs9937. Using patients with 0 or 1 variant as reference, patients with 2 variants had an increased HR of 1.79 (P = 0.004) and patients with 3-4 variants has an increased HR of 3.25 (P < 0.001). There were also two SNPs in this study that, when taken together, affected tumor response to therapy: rs2072671 and rs760370. Using patients with 0 variants as reference, patients with 1-2 variants had an increased OR of 3.40 (P = 0.004).	Genotype AA is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AC + CC.	20665488	981793945